One Bio

Cover Block

PUBLIC

Name	One Bio
Tagline	Developing proprietary short-chain, anti-inflammatory plant fibers from agricultural waste for food and biopharma.
Headquarters	Sacramento, United States
Founded	2019
Stage	Series A
Business Model	B2B
Industry	Agtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Series A (total disclosed ~$27,000,000)

Links

PUBLIC

• Website: https://www.one.bio
• LinkedIn: https://www.linkedin.com/company/onebioinc

Executive Summary

PUBLIC One Bio is a biotechnology company that converts agricultural waste into imperceptible, functional fibers, a technical approach to the fiber gap that has secured a $27 million Series A from a syndicate of venture and strategic investors [AgFunderNews, December 2024]. The company, a 2019 spinout from UC Davis, operates at the intersection of food science and biopharma, developing short-chain oligosaccharides designed to modulate the microbiome and immune response without altering the taste or texture of consumer products [one.bio, retrieved 2026]. Its core technology platform, which includes a proprietary database of fiber structures called The Glycopedia, aims to reintroduce bioactive compounds lost in modern food processing [one.bio, retrieved 2026].

The founding team combines deep academic roots in food science from UC Davis with later-stage operational experience, notably through the addition of Matt Barnard, cofounder of vertical farming company Plenty, as CEO in 2023 [AgFunderNews, December 2024]. The recent funding round, led by Alpha Edison, included strategic capital from Leaps by Bayer and DSM-Firmenich, signaling industrial validation for its ingredient-as-a-service business model targeting food, beverage, and supplement manufacturers [Axios, December 2024]. Over the next 12-18 months, the key milestones to watch are the transition from pilot-scale production to commercial supply agreements and the publication of clinical data validating the health claims of its WholeFibers™ platform.

Data Accuracy: GREEN -- Core company description, funding details, and founding story corroborated by multiple independent sources including AgFunderNews, Axios, and the company website.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	B2B
Industry / Vertical	Agtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Series A (total disclosed ~$27,000,000)

Company Overview

PUBLIC

One Bio operates as a biotechnology ingredient company, but its origins are firmly rooted in academic research. The company is a spinout from the University of California, Davis, where foundational work on dietary fiber and its biological effects was conducted [AgFunderNews, December 2024]. It was incorporated in 2019 and is headquartered in Sacramento, California [Crunchbase]. The company's initial identity was BCD Bioscience, a name it used before rebranding to One Bio to reflect its broader mission [LinkedIn].

The company's primary public milestone is its $27 million Series A financing round, which closed in December 2024 and was led by Alpha Edison [AgFunderNews, December 2024]. This capital event followed an earlier, undisclosed seed round that attracted a syndicate of venture capital firms, including Acre Venture Partners, Amplify.LA, and Fika Ventures [Startup Intros]. A significant leadership change occurred in 2023 with the addition of Matt Barnard, cofounder of vertical farming firm Plenty, who joined as cofounder and CEO [AgFunderNews, December 2024].

Data Accuracy: GREEN -- Confirmed by AgFunderNews, Crunchbase, and LinkedIn.

Product and Technology

MIXED One Bio's core proposition is the conversion of agricultural waste into a functional food ingredient, a process that aims to address a fundamental nutritional deficit in modern diets. The company's proprietary WholeFibers™ are short-chain plant fibers, or oligosaccharides, derived from materials like plant stems, seeds, and nut shells [Perplexity Sonar Pro Brief]. The platform's technical wedge is its ability to render these fibers odorless, colorless, and tasteless, allowing for high inclusion rates of 20 grams or more in foods and beverages without altering their sensory profile [cbinsights.com]. This positions the ingredient as a solution for formulators seeking to boost fiber content in processed foods, a category historically linked to fiber loss.

The underlying science is framed around reintroducing "active fibers" that support the gut microbiome and modulate immune function [Perplexity Sonar Pro Brief]. The company has developed a scientific resource called The Glycopedia, described as a database mapping fiber structures to their fermentation pathways and biological effects [one.bio, retrieved 2026]. This suggests a discovery and formulation engine that could enable targeted ingredient development. While specific processing methods are not detailed publicly, the company's active hiring for a Pilot Plant Operator role in Sacramento [LinkedIn, retrieved 2026] indicates ongoing scale-up of its production capabilities, an inference drawn from the job posting.

Commercial application is directed at multiple verticals. The primary focus is on food and beverage companies, with a noted emphasis on products marketed as "GLP-1 friendly" to cater to consumers using weight-management medications [thespoon.tech, retrieved 2026]. A secondary, longer-term application is suggested for the biopharmaceutical sector, where the immune-modulating properties of the fibers could be leveraged [Perplexity Sonar Pro Brief]. The recent Series A investment from ingredient giant DSM-Firmenich [AgFunderNews, December 2024] provides a potential route to market validation and commercial integration, though no publicly announced customer deployments or product launches have been cited.

Data Accuracy: GREEN -- Product claims and technology description are consistently reported across multiple trade publications and the company's own website. The inference regarding production scale-up is based on a public job posting.

Market Research

PUBLIC

The market for functional food ingredients that address specific health deficiencies is expanding, driven by consumer demand for science-backed nutrition and the food industry's need for clean-label, high-performance additives.

Quantifying the total addressable market for One Bio's short-chain fibers is challenging due to the specificity of the ingredient and its dual food and biopharma applications. No third-party TAM/SAM/SOM analysis specific to this niche is cited in public sources. However, analogous market reports provide context. The global dietary fibers market was valued at approximately $8.9 billion in 2024 and is projected to grow at a compound annual growth rate of 12.5% through 2032, according to a report cited by AgFunderNews [AgFunderNews, December 2024]. The broader functional food ingredients market, which includes prebiotics, probiotics, and other bioactive compounds, is a multi-billion dollar segment within the larger food and beverage industry.

Several converging demand drivers underpin the opportunity for One Bio's technology. The primary tailwind is the persistent "fiber gap" in modern diets, where processed foods are energy-dense but fiber-poor, a deficiency linked to chronic inflammation and metabolic disease [AgFunderNews, December 2024]. Consumer awareness of gut microbiome health as a cornerstone of overall wellness continues to grow, creating demand for ingredients that deliver tangible prebiotic benefits. A more recent and specific driver is the rapid adoption of GLP-1 agonist medications for weight management, which has created a new category of "GLP-1 friendly" foods designed to combat side effects like muscle loss and nutrient deficiency; high-fiber, protein-rich formulations are central to this trend [thespoon.tech, retrieved 2026]. One Bio explicitly positions its WholeFibers™ as ingredients for this emerging product category.

Key adjacent and substitute markets include the broader prebiotic ingredient space, which encompasses fibers like inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS), as well as other microbiome-modulating compounds. The market for anti-inflammatory supplements and nutraceuticals is another adjacent space, where One Bio's fibers could potentially be positioned for their immune-modulating properties. On the substitute side, whole food sources of fiber and other bulk-forming agents used for texture in food processing represent established, lower-cost alternatives, though they typically lack the targeted biological activity and sensory neutrality of One Bio's offering.

Regulatory and macro forces are generally favorable but require navigation. In the food sector, ingredients must generally be recognized as safe (GRAS) by the FDA, a process that can be lengthy and costly. The use of agricultural waste as a feedstock aligns with powerful macro trends around circular economy and sustainability, potentially offering cost advantages and appealing to environmentally conscious brands and consumers. However, supply chain consistency for agricultural waste streams and scalability of the proprietary conversion process present operational challenges that must be solved for commercial success.

Metric	Value
Global Dietary Fibers Market (2024)	8.9 $B
Projected CAGR (2024-2032)	12.5 %

The projected growth rate for the dietary fibers market, while not specific to One Bio's novel oligosaccharides, indicates strong underlying demand and a receptive environment for innovation. The company's bet is that its proprietary, sensorily neutral fibers can capture a premium segment of this expanding market by solving formulation challenges that have limited high-dose fiber inclusion in the past.

Data Accuracy: YELLOW -- Market sizing is based on an analogous sector report cited in trade press; specific TAM for short-chain plant fibers is not publicly available.

Competitive Landscape

MIXED One Bio operates in a competitive space defined by established ingredient suppliers, specialized fiber producers, and a growing number of startups targeting the functional food and microbiome health markets.

Given the absence of specific named competitors in the structured research, a direct comparison table is omitted. The competitive analysis proceeds as prose, mapping the landscape based on the company's stated positioning.

Competition for One Bio's WholeFibers™ can be segmented into three broad categories. First, large-scale ingredient incumbents like ADM, Ingredion, and Tate & Lyle offer a wide portfolio of traditional and modified fibers (e.g., inulin, soluble corn fiber). Their advantages are global scale, established food industry relationships, and proven supply chains. However, their products often face sensory and inclusion-rate limitations that One Bio's technology is designed to overcome. Second, a cohort of specialized fiber and prebiotic startups, such as Brightseed (phytonutrient discovery) and ZBiotics (engineered probiotics), are also targeting the gut health and functional ingredient space, though their technological approaches differ. Third, adjacent substitutes include whole food ingredients and over-the-counter fiber supplements (e.g., psyllium husk, acacia fiber), which compete on price and consumer familiarity but lack the proprietary, high-dose, imperceptible formulation profile that One Bio claims.

One Bio's current defensible edge appears to rest on its proprietary processing technology and its scientific foundation. The company's platform, which converts agricultural waste polysaccharides into short-chain, tasteless fibers, is a specific technical claim not broadly advertised by the large incumbents [Perplexity Sonar Pro Brief]. Its academic origin as a UC Davis spinout and the development of 'The Glycopedia' database of fiber structures and biological effects provide a research-based moat [one.bio, retrieved 2026]. This edge is durable if protected by strong intellectual property and if the database's predictive power for health outcomes proves superior. However, it is perishable if larger competitors with deeper R&D budgets develop similar processes or if the science behind specific fiber structures becomes commoditized.

The company's primary exposure lies in commercialization and scale. While it has secured strategic investors like Leaps by Bayer and DSM-Firmenich, these are not yet public commercial partnerships [AgFunderNews, December 2024]. Incumbents own the deep, long-term relationships with major food and beverage conglomerates, which are notoriously slow to adopt new ingredients. One Bio must prove not only technical efficacy but also cost-effectiveness at industrial scale and navigate complex regulatory pathways (e.g., GRAS status in the U.S.) for its novel fibers. A competitor with a similar scientific claim but a faster path to regulatory approval or a lower-cost production method could capture first-mover advantages in key product categories.

The most plausible 18-month competitive scenario hinges on the conversion of investor interest into commercial traction. If One Bio can announce a flagship partnership with a major food or supplement brand to launch a product containing WholeFibers™, it would validate its value proposition and create a reference customer that others would follow. In this scenario, the 'winner' would be the startup that first demonstrates clear consumer demand for its specific fiber profile, likely through a partnership with a company like Nestlé or PepsiCo's emerging health-focused brands. The 'loser' would be any pure-play fiber startup that remains in the pilot or ingredient sampling phase without a clear path to a scaled, branded product on shelves, as capital patience for pre-revenue science stories in food tech may wane.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated market and technology; no direct competitor names were provided in cited sources.

Opportunity

PUBLIC The prize for One Bio is a foundational position in the next generation of functional food ingredients, turning the multi-billion-dollar fiber deficiency into a recurring, high-margin ingredient business.

The headline opportunity is to become the default supplier of invisible, high-dose fiber to the global processed food industry. The company's technology, which allows for inclusion rates of 20 grams or more without altering taste or texture, directly addresses the primary barrier to fiber fortification in mass-market products [cbinsights.com]. This positions WholeFibers™ not as a niche additive but as a core ingredient for reformulation across categories from bread to beverages. The plausibility of this outcome is underscored by the strategic composition of its Series A syndicate, which includes Leaps by Bayer and DSM-Firmenich, two entities with deep commercial channels into global food and nutrition markets [AgFunderNews, December 2024]. Their investment is a tangible signal that industry incumbents see the technology as a viable path to market.

Several concrete growth scenarios could propel the company toward that headline outcome. The most immediate is leveraging the current consumer and pharmaceutical focus on GLP-1 medications, which has created a surge in demand for satiety-supporting, nutrient-dense "GLP-1 friendly" foods [thespoon.tech].

Scenario	What happens	Catalyst	Why it's plausible
GLP-1 Ingredient Standard	One Bio becomes the go-to fiber supplier for a wave of new products targeting consumers on weight-loss drugs.	A public partnership or co-branded product launch with a major food or supplement brand.	The company is already publicly positioning its fibers for this use case, and investor DSM-Firmenich has existing commercial relationships in the space [thespoon.tech] [AgFunderNews, December 2024].
Biopharma Platform Expansion	The proprietary oligosaccharides prove effective in clinical settings, creating a high-value pharmaceutical ingredients business.	Publication of peer-reviewed research or a development partnership with a pharma company.	The company's foundational research originates from UC Davis, and its stated mission includes biopharmaceutical applications, attracting investors like Leaps by Bayer which focuses on breakthrough therapeutics [one.bio] [AgFunderNews, December 2024].
Waste Stream Monetization	The process of deriving fibers from agricultural waste becomes a cost and sustainability advantage, locking in supply partnerships.	Securing long-term, low-cost feedstock agreements with major agricultural processors.	The core technology begins with agricultural waste polysaccharides, aligning with broader industry sustainability goals and potentially creating a dual revenue stream from waste valorization [Perplexity Sonar Pro Brief].

What compounding looks like for One Bio is a data and formulation flywheel. The company has developed 'The Glycopedia', a database mapping fiber structures to their biological effects [one.bio]. Each new customer formulation and potential clinical study feeds data back into this platform, refining the understanding of which fiber profiles work best for specific health outcomes. This proprietary knowledge base could become a significant moat, making it increasingly difficult for competitors to match the precision and efficacy of WholeFibers™ without years of comparable R&D. Early evidence of this flywheel is the platform's existence itself, suggesting a research-driven approach beyond a single ingredient.

The size of the win can be framed by looking at comparable ingredient companies. For instance, Kerry Group, a global taste and nutrition solutions company, carries a market capitalization of approximately $13 billion, with a significant portion of its business built on proprietary, value-added food ingredients. If One Bio successfully executes on the "GLP-1 Ingredient Standard" scenario and captures a meaningful share of the functional fiber segment within the broader nutrition ingredients market, a multi-billion dollar valuation is a plausible outcome. This is a scenario, not a forecast, but it illustrates the scale of the opportunity in becoming a branded, science-backed ingredient leader rather than a commodity supplier.

Data Accuracy: GREEN -- Core opportunity claims (technology wedge, investor syndicate, GLP-1 positioning) are confirmed by multiple independent trade publications and the company's own materials.

Sources

PUBLIC

1. [AgFunderNews, December 2024] UC Davis spinoff One Bio raises $27m Series A to bridge the fiber gap | https://agfundernews.com/uc-davis-spinoff-one-bio-raises-27m-series-a-to-bridge-the-fiber-gap

2. [one.bio, retrieved 2026] one.bio | Restore the Missing Fiber Signal Your Body Needs | https://www.one.bio/

3. [Axios, December 2024] Food tech fiber startup One Bio raises $27M Series A | https://www.axios.com/pro/retail-deals/2024/12/12/food-tech-startup-specialty-ingredients-one-bio-venture-capital-funding

4. [Crunchbase] one.bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/one-bio

5. [Startup Intros] one.bio: Funding, Team & Investors | https://startupintros.com/orgs/one-bio

6. [LinkedIn] one.bio | LinkedIn | https://www.linkedin.com/company/onebioinc

7. [Perplexity Sonar Pro Brief] One Bio (one.bio) company brief | https://www.perplexity.ai/

8. [cbinsights.com] one.bio - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/bcd-bioscience

9. [LinkedIn, retrieved 2026] one.bio hiring Pilot Plant Operator in Sacramento, CA | https://www.linkedin.com/jobs/view/pilot-plant-operator-at-one-bio-4166528231

10. [thespoon.tech, retrieved 2026] One Bio Raises $27M to Advance Short-Chain Fiber Ingredients for GLP-1 Friendly Foods | https://thespoon.tech/one-bio-raises-27m-to-advance-short-chain-fiber-for-glp-1-friendly-foods/